AQP1 and Polyhydramnios: The data obtained from AQP-KO mice studies suggest AQP1 inhibitors may have clinical indications as diuretics and the glaucoma, cerebral edema, elevated intraocular pressure, malignancies, and other conditions directly or indirectly related to abnormal fluid homeostasis, whereas AQP1 induction might be applied to treat polyuria, polyhydramnios, cataract, to accelerate wound healing, or to facilitate organ regeneration.